{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:03:46Z","timestamp":1788303826677,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03153-3","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:31:12Z","timestamp":1742387472000},"page":"2354-2368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["An Up-to-Date Description of the Use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Italy: Evidence from Real Clinical Practice"],"prefix":"10.1007","volume":"42","author":[{"given":"Valentina","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ciappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Lucatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cinti Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"3153_CR1","doi-asserted-by":"publisher","DOI":"10.24926\/iip.v12i3.4228","author":"J Stearns","year":"2021","unstructured":"Stearns J, Cortese C, Remington J, Patil N. Evaluation of prescribing and administering as-needed pain medications based on pain severity scores. Innov Pharm. 2021. https:\/\/doi.org\/10.24926\/iip.v12i3.4228.","journal-title":"Innov Pharm"},{"issue":"3","key":"3153_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4415\/ANN_18_03_05","volume":"54","author":"V Damico","year":"2018","unstructured":"Damico V, Murano L, Cazzaniga F, Dal Molin A. Pain prevalence, severity, assessment and management in hospitalized adult patients: a result of a multicenter cross sectional study. Ann Ist Super Sanita. 2018;54(3):194\u2013200. https:\/\/doi.org\/10.4415\/ANN_18_03_05.","journal-title":"Ann Ist Super Sanita"},{"key":"3153_CR3","unstructured":"World Health Organization. Cancer pain relief. World Health Organization. 1986. Available at: https:\/\/iris.who.int\/handle\/10665\/43944. Accessed 3 Feb 2025."},{"issue":"9","key":"3153_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/ijerph21091135","volume":"21","author":"I Kova\u010devi\u0107","year":"2024","unstructured":"Kova\u010devi\u0107 I, Pavi\u0107 J, Filipovi\u0107 B, Ozimec Vulinec \u0160, Ili\u0107 B, Petek D. Integrated approach to chronic pain-the role of psychosocial factors and multidisciplinary treatment: a narrative review. Int J Environ Res Public Health. 2024;21(9):1135. https:\/\/doi.org\/10.3390\/ijerph21091135.","journal-title":"Int J Environ Res Public Health"},{"key":"3153_CR5","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.2147\/IJGM.S419239","volume":"16","author":"NM Alorfi","year":"2023","unstructured":"Alorfi NM. Pharmacological methods of pain management: narrative review of medication used. Int J Gen Med. 2023;16:3247\u201356. https:\/\/doi.org\/10.2147\/IJGM.S419239.","journal-title":"Int J Gen Med"},{"issue":"5","key":"3153_CR6","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","volume":"125","author":"LR Webster","year":"2017","unstructured":"Webster LR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741\u20138. https:\/\/doi.org\/10.1213\/ANE.0000000000002496.","journal-title":"Anesth Analg"},{"issue":"1","key":"3153_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40360-016-0081-x","volume":"17","author":"DP Primejdie","year":"2016","unstructured":"Primejdie DP, Bojita MT, Popa A. Potentially inappropriate medications in elderly ambulatory and institutionalized patients: an observational study. BMC Pharmacol Toxicol. 2016;17(1):38. https:\/\/doi.org\/10.1186\/s40360-016-0081-x.","journal-title":"BMC Pharmacol Toxicol"},{"key":"3153_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4857","volume":"354","author":"A Arf\u00e8","year":"2016","unstructured":"Arf\u00e8 A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354: i4857. https:\/\/doi.org\/10.1136\/bmj.i4857.","journal-title":"BMJ"},{"issue":"2","key":"3153_CR9","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.4081\/or.2014.5309","volume":"6","author":"G Fanelli","year":"2014","unstructured":"Fanelli G, Cherubino P, Compagnone C. Opioid use for chronic pain management in Italy: results from the Orthopedic Instant Pain Survey Project. Orthop Rev (Pavia). 2014;6(2):5309. https:\/\/doi.org\/10.4081\/or.2014.5309.","journal-title":"Orthop Rev (Pavia)"},{"issue":"1","key":"3153_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s44158-023-00121-7","volume":"3","author":"S Mercadante","year":"2023","unstructured":"Mercadante S. Houston, we have a problem of opioid crisis\u2026 and Rome? J Anesth Analg Crit Care. 2023;3(1):36. https:\/\/doi.org\/10.1186\/s44158-023-00121-7.","journal-title":"J Anesth Analg Crit Care"},{"issue":"2","key":"3153_CR11","doi-asserted-by":"publisher","first-page":"2242248","DOI":"10.1080\/07853890.2023.2242248","volume":"55","author":"RI Farah","year":"2023","unstructured":"Farah RI, Khatib AE, Abu Ziyad HJ, et al. Pattern of use and awareness of side-effects of non-steroidal anti-inflammatory drugs in the Jordanian population. Ann Med. 2023;55(2):2242248. https:\/\/doi.org\/10.1080\/07853890.2023.2242248.","journal-title":"Ann Med"},{"issue":"1","key":"3153_CR12","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1038\/s41598-024-56665-3","volume":"14","author":"Z Salis","year":"2024","unstructured":"Salis Z, Sainsbury A. Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5\u00a0years. Sci Rep. 2024;14(1):6593. https:\/\/doi.org\/10.1038\/s41598-024-56665-3.","journal-title":"Sci Rep"},{"issue":"1","key":"3153_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.5301\/heartint.5000227","volume":"10","author":"V Orlando","year":"2016","unstructured":"Orlando V, Menditto E, Guerriero F, Rotunno R. Effectiveness of the CardioPain initiative in reducing inappropriate NSAID prescriptions in pain therapy among high cardiovascular risk patients: an informative Italian survey. Heart Int. 2016;10(1):e20\u20134. https:\/\/doi.org\/10.5301\/heartint.5000227.","journal-title":"Heart Int"},{"issue":"3","key":"3153_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2021.1965988","volume":"21","author":"MJ Domper Arnal","year":"2022","unstructured":"Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022;21(3):373\u201384. https:\/\/doi.org\/10.1080\/14740338.2021.1965988.","journal-title":"Expert Opin Drug Saf"},{"key":"3153_CR15","unstructured":"AIFA (Italian Medicines Agency). The use of drugs in Italy. National report 2022. Available at: https:\/\/www.aifa.gov.it\/-\/l-uso-dei-farmaci-in-italia-rapporto-osmed-2022. Accessed 3 Feb 2025."},{"key":"3153_CR16","unstructured":"AIFA (Italian Medicines Agency). The use of drugs in Italy. National report 2023. Available at: https:\/\/www.aifa.gov.it\/-\/l-uso-dei-farmaci-in-italia-rapporto-osmed-2023. Accessed 3 Feb 2025."},{"key":"3153_CR17","unstructured":"European Medicines Agency update on review of non-selective NSAIDs. Available at: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-update-review-non-selective-nsaids. Accessed 3 Feb 2025."},{"key":"3153_CR18","unstructured":"AIFA (Italian Medicines Agency). FANS e rischi cardiovascolari AIFA (Italian Medicines Agency). https:\/\/www.aifa.gov.it\/-\/fans-e-rischi-cardiovascolari. Accessed 3 Feb 2025."},{"issue":"4","key":"3153_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.annonc.2021.12.009","volume":"33","author":"S Mercadante","year":"2022","unstructured":"Mercadante S. Too much for some and too little for others. Ann Oncol. 2022;33(4):445. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.009.","journal-title":"Ann Oncol"},{"issue":"1","key":"3153_CR20","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/S1473-3099(22)00433-9","volume":"23","author":"N Perico","year":"2023","unstructured":"Perico N, Cortinovis M, Suter F, Remuzzi G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect Dis. 2023;23(1):e22\u201333. https:\/\/doi.org\/10.1016\/S1473-3099(22)00433-9.","journal-title":"Lancet Infect Dis"},{"key":"3153_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.935280","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang J, Sheng H, Tang X, et al. Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19. Front Cell Infect Microbiol. 2022;12: 935280. https:\/\/doi.org\/10.3389\/fcimb.2022.935280.","journal-title":"Front Cell Infect Microbiol"},{"key":"3153_CR22","unstructured":"AIFA (Italian Medicines Agency). Aggiornamento della Nota 66 (Determina 10 ottobre 2018). Available at: https:\/\/www.aifa.gov.it\/documents\/20142\/241076\/Modifica_alla_Nota_66-G.U._n._246_del_22.10.2018.pdf. Accessed 3 Feb 2025."},{"issue":"12","key":"3153_CR23","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.181424.","journal-title":"Circulation"},{"issue":"2","key":"3153_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.adaj.2015.07.020","volume":"147","author":"A Aminoshariae","year":"2016","unstructured":"Aminoshariae A, Kulild JC, Donaldson M. Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects: an updated systematic review. J Am Dent Assoc. 2016;147(2):98\u2013110. https:\/\/doi.org\/10.1016\/j.adaj.2015.07.020.","journal-title":"J Am Dent Assoc"},{"issue":"2","key":"3153_CR25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/SPC.0000000000000332","volume":"12","author":"J Strawson","year":"2018","unstructured":"Strawson J. Nonsteroidal anti-inflammatory drugs and cancer pain. Curr Opin Support Palliat Care. 2018;12(2):102\u20137. https:\/\/doi.org\/10.1097\/SPC.0000000000000332.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"3153_CR26","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1038\/s41598-024-56665-3","volume":"14","author":"Z Salis","year":"2024","unstructured":"Salis Z, Sainsbury A. Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis: a prospective multi-cohort study over 4-to-5 years. Sci Rep. 2024;14(1):6593. https:\/\/doi.org\/10.1038\/s41598-024-56665-3.","journal-title":"Sci Rep"},{"issue":"2","key":"3153_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4068\/cmj.2023.59.2.115","volume":"59","author":"NMP Maideen","year":"2023","unstructured":"Maideen NMP. Adverse effects associated with long-term use of proton pump inhibitors. Chonnam Med J. 2023;59(2):115\u201327. https:\/\/doi.org\/10.4068\/cmj.2023.59.2.115.","journal-title":"Chonnam Med J"},{"issue":"9","key":"3153_CR28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/ijerph16091571","volume":"16","author":"BKS Thong","year":"2019","unstructured":"Thong BKS, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health. 2019;16(9):1571. https:\/\/doi.org\/10.3390\/ijerph16091571.","journal-title":"Int J Environ Res Public Health"},{"key":"3153_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1909","volume":"357","author":"M Bally","year":"2017","unstructured":"Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017;357: j1909. https:\/\/doi.org\/10.1136\/bmj.j1909.","journal-title":"BMJ"},{"issue":"1","key":"3153_CR30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12882-017-0673-8","volume":"18","author":"X Zhang","year":"2017","unstructured":"Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017;18(1):256. https:\/\/doi.org\/10.1186\/s12882-017-0673-8.","journal-title":"BMC Nephrol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03153-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03153-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03153-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:51:09Z","timestamp":1744872669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03153-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03153-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maria Ciappetta and Domenico Lucatelli are employees of Angelini Pharma S.p.A, Italy. Valentina Perrone, Chiara Veronesi, Andrea Cinti Luciani, Luca Degli Esposti have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approval has been obtained from the following ethics committees of the involved: authorization of the Ethics Committee \u201cBAT (Barletta-Andria-Trani) Comitato etico interprovinciale Area I\u201d (protocol number 68\/CE\/20, approval date 3\/12\/2020); authorization of the Ethics Committee \u201cBerica Comitato Etico per le Sperimentazioni Cliniche (CESC) della Provincia di Vicenza\u201d (protocol number 1627, approval date 28\/10\/2020); authorization of the Ethics Committee of Bergamo (protocol number 330, approval date 6\/4\/2023); authorization of the Ethics Committee \u201cBrindisi Comitato Indipendente di Etica Medica\u201d (protocol number 48148, approval date 28\/05\/2021); authorization of the \u201cRegional Ethics Committee Liguria\u201d (protocol number 797\/2021, approval date 14\/03\/2022); authorization of the Ethics Committee \u201cFrosinone Comitato Etico Lazio 2\u201d (protocol number 0179046\/2020, approval date 28\/10\/2020); authorization of the Ethics Committee \u201cNapoli 3 Comitato Etico Interaziendale Campania Sud\u201d (protocol number 51, approval date 02\/09\/2020); authorization of the Ethics Committee \u201cComitato Etico Palermo 1\u201d (protocol number 02\/2021, approval date 24\/02\/2021); authorization of the Ethics Committee \u201cPedemontana Comitato Etico per le Sperimentazioni Cliniche (CESC) della Provincia di Vicenza\u201d (protocol number 0036999, approval date 28\/04\/2021); authorization of the Ethics Committee \u201cRoma 3 Comitato Etico Lazio 2\u201d (protocol number 0031200\/2021, approval date 10\/02\/2021); authorization of the Ethics Committee \u201cRoma 4 Comitato Etico Lazio 1\u201d (protocol number 1079\/CE Lazio 1, approval date 23\/09\/2020); authorization of the Ethics Committee \u201cRoma 5 Comitato Etico Lazio 1\u201d (protocol number 1166\/CE Lazio 1, approval date 12\/10\/2020); authorization of the Ethics Committee \u201cRoma 6 Comitato Etico Lazio 2\u201d (protocol number 0216084\/2020, approval date 16\/12\/2020); authorization of the Ethics Committee \u201cSerenissima Comitato Etico per la Sperimentazione Clinica della provincia di Venezia Comitato Etico per la Sperimentazione Clinica della provincia di Venezia (protocol number 05.08, approval date 08\/10\/2020); authorization of the Ethics Committee \u201cUmbria 2 Comitato Etico Regionale Umbria\u201d (protocol number 19414\/20\/ON, approval date 16\/09\/2020); authorization of the Ethics Committee \u201cVercelli Comitato Etico Interaziendale A.O. SS. Antonio e Biagio e Cesare Arrigo \u2013 Alessandria\u201d (protocol number 0008668, approval date 20\/04\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}